Showing results (181-190 of 270) with videos related to

Sort By:
Pageof 27
Molecular Genetics and Metabolism|June 12, 2025
Treatment preferences of adult patients with hereditary fructose intolerance: A discrete choice experimentLise E F Janssen, Mickaël Hiligsmann, Corrie Timmer, et al.
Talanta|March 11, 2014
Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MSD H Vu, R A Koster, M S Bolhuis, et al.
British Journal of Clinical Pharmacology|May 21, 2004
Leflunomide in active rheumatoid arthritis: a prospective study in daily practiceE N Van Roon, T L Th A Jansen, L Mourad, et al.
British Journal of Clinical Pharmacology|July 17, 2004
Leflunomide in active rheumatoid arthritis: a prospective study in daily practiceE N Van Roon, T L Th A Jansen, L Mourad, et al.
Annals of the Rheumatic Diseases|February 6, 2008
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinolM K Reinders, E N van Roon, T L Th A Jansen, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|February 3, 2009
Plasma triglycerides and LDL cholesterol are related in a parabolic fashion in the general population and patients with Type 2 diabetes mellitus: long-term follow-up results from the Hoorn studyM C G J Brouwers, J M Dekker, M M J van Greevenbroek, et al.
Clinical Endocrinology|September 15, 2021
Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation studyPomme I H G Simons, Merel E B Cornelissen, Olivier Valkenburg, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritisE N van Roon, T L T A Jansen, M A F J van de Laar, et al.
Clinical Therapeutics|October 8, 2009
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacistsEric N van Roon, Patricia M L A van den Bemt, Tim L Th A Jansen, et al.
Diabetes, Obesity & Metabolism|November 3, 2017
A risk score including body mass index, glycated haemoglobin and triglycerides predicts future glycaemic control in people with type 2 diabetesDorijn F L Hertroijs, Arianne M J Elissen, Martijn C G J Brouwers, et al.
Pageof 27